BioInsights - Leveraging LAG-3 for improved patient outcomes

Leveraging LAG-3 for improved patient outcomes

Immuno-Oncology Insights 2022; 3(1), 7–11


Published: 24 January 2022
Paul Basciano

Paul Basciano is an executive director, development program lead at Bristol Myers Squibb, which he joined in 2015. While there, he has had various roles in oncology clinical drug development spanning from first in human through registrational studies, as well as leading the oncology clinical collaborations portfolio. Before joining BMS, Paul completed medical school at Columbia University College of Physicians and Surgeons, followed by a residency in internal medicine and fellowship in hematology and oncology at New York Presbyterian Hospital-Weill Cornell. While at Cornell, he held the position of Assistant Professor of Medicine as a clinician-scientist in hematology and oncology, treating patients with hematologic disorders and leading a translational research laboratory studying the role of the cytoskeleton in hematologic disorders.